Altimmune Inc.
05/20/2022 | Press release | Distributed by Public on 05/20/2022 05:36
Altimmune to Present Pemvidutide Clinical Data at Upcoming Global NASH Congress May 27, 2022
GAITHERSBURG, Md., May 20, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will give an oral presentation at the 5thGlobal NASH Congress on May 26-27, 2022, in London, UK. His presentation will provide an overview of pemvidutide, the Company's novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of obesity and NASH. Dr. Harris will also moderate a panel discussion on clinical endpoints in NASH trials.
Details for the oral presentation are as follows:
| Title: | The Emerging Weight Loss Therapeutics and Implications for the NASH Treatment Paradigm |
| Presenter: | Scott Harris, M.D., Chief Medical Officer, Altimmune, Inc. |
| Date/Time: | Friday, May 27, 2022 at 3:15 pm GMT |
A copy of Dr. Harris' presentation will be accessible on the Events section of the Altimmune website.
Details for the panel discussion are as follows:
| Title: | Clinical Endpoints for NASH Trials |
| Moderator: | Scott Harris, M.D., Chief Medical Officer, Altimmune, Inc. |
| Date/Time: | Friday, May 27, 2022 at 9:35 am GMT |
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Investor & Media Contacts:
Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
[email protected]
Source: Altimmune, Inc